Sonnet Biotherapeutics Holdings Inc (SONN) Stock Analysis

Sonnet Biotherapeutics Holdings Inc (SONN) is a publicly traded company in the HEALTHCARE sector. It trades at $1.26. This page summarizes the public market data, fundamentals, and frequently asked questions for SONN, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $1.26

About Sonnet Biotherapeutics Holdings Inc

Sonnet Biotherapeutics Holdings Inc. is a cutting-edge biotechnology company headquartered in Princeton, New Jersey, specializing in the development of novel oncological therapies through its proprietary platform for single-acting and bispecific biologics. By harnessing advanced technology, Sonnet is committed to creating targeted treatments that effectively address significant unmet medical needs in cancer care. With a strategic focus on next-generation biologics, the company is poised to le...

GNG Research Analysis

GNG Research scores Sonnet Biotherapeutics Holdings Inc (SONN) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for SONN.

Frequently Asked Questions

Does SONN pay dividends?

Sonnet Biotherapeutics Holdings Inc (SONN) does not currently pay a regular dividend.